ArticleClinics in colon and rectal surgery2011
Gastrointestinal tumors of the colon and rectum.
Article in Clinics in colon and rectal surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Local excision and radical excision for rectal gastrointestinal stromal tumors: a meta-analysis protocol.Frontiers in oncology · 2023Pooled it
- Incidental Discovery of a Sigmoid Colon Gastrointestinal Stromal Tumor Mimicking Colitis: A Case Report.Cureus · 2025Article
- Rectal Gastrointestinal Stromal Tumors.Cureus · 2023Article
- Clinicopathological features and prognosis of colonic and rectal gastrointestinal stromal tumors: A propensity score matching analysis.Frontiers in surgery · 2022Article
- Transvaginal Resection of a Rectal Gastrointestinal Stromal Tumor: A Case Report.Journal of medical cases · 2021Article
- Multifocal gastrointestinal stromal tumor: A case report with CT, surgical, and histopathologic correlation.Radiology case reports · 2019Article
- Management of low rectal gastrointestinal stromal tumor with neoadjuvant therapy and transanal excision: a rare case report and review of the literature.International journal of general medicine · 2019Article
- Management of rectal gastrointestinal stromal tumor.Translational gastroenterology and hepatology · 2018Review
- The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.Annals of the Royal College of Surgeons of England · 2015Article
- Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec).BMJ case reports · 2015Article
- Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy.World journal of surgical oncology · 2014Article
- Clinicopathologic factors predicting outcomes in patients with gastrointestinal stromal tumors of the rectum and colon.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Robot-assisted excision of a pararectal gastrointestinal stromal tumor in a patient with previous ileal neobladder.Case reports in urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) of the colon and rectum are the most common mesenchymal tumors of the gastrointestinal tract. GISTs of the colon and rectum constitute ~5% of all cases. Although colorectal GISTs can be small and found incidentally, the majority appear to be high risk and carry a significant likelihood of recurrent and metastatic disease. Surgery remains the mainstay of treatment for primary disease. There is now considerable interest in GISTs because they can be treated effectively with targeted molecular therapies, specifically tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. GISTs are best treated by a multidisciplinary team comprised of the surgeon, medical oncologist, pathologist, and radiologist in the initial evaluation, management, and in continued follow-up. Increasing the number of resectable cases through pharmacologic debulking, optimizing the timing of surgery and organ preservation, reducing recurrence and surgical morbidity, prolonging survival, and possibly enhancing response to imatinib through surgical cytoreduction are all potential benefits of multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.